were among the best-performing health-related stocks Monday, vaulting 38% after the maker of medical tests posted a narrower first-quarter loss and announced a collaboration agreement with
(PFE - Get Report)
Monogram reported a loss of $3.4 million, or 3 cents a share, on revenue of $13.2 million. Excluding stock-based compensation costs, the company recorded a loss of $1.5 million, or 1 cent a share. Last year, the company posted a first-quarter loss of $7.4 million, or 6 cents a share, on revenue of $10 million. Excluding items, the year-ago loss was $4.1 million, or 3 cents a share.
Pfizer will invest $25 million in Monogram as part of the companies' collaboration. The investment will "provide a substantial injection of capital to facilitate our continued growth and development and also represents a huge endorsement of our role as the partner of choice for companies with significant HIV development programs," Monogram said. The investment is being made through a 3% convertible note due 2010. The multi-year agreement aims to help Monogram make its HIV co-receptor Tropism assay available for patient use on a worldwide basis. Shares of Monogram were trading up 65 cents to $2.34.
(IART - Get Report)
fell 4% after the medical-device maker posted soft revenue for the first quarter and offered a second-quarter revenue guidance that fell short as well. The company's first-quarter earnings were $8.7 million, or 28 cents a share, up from $8.4 million, or 26 cents a share, a year earlier. Excluding restructuring charges, Integra posted earnings of 31 cents a share. Revenue rose to $77.1 million from $65.8 million. Analysts polled by Thomson First Call expected earnings of 28 cents a share and revenue of $80.4 million.
Looking ahead, Integra sees second-quarter earnings of 31 cents to 34 cents a share, excluding restructuring charges. The company predicts revenue of $87 million to $92 million. Analysts project earnings of 32 cents a share on revenue of $92.6 million. Shares were down $1.90 to $40.92.